Malvern-based Ocugen announced positive feedback for pediatric clinical testing of its version of the COVID-19 vaccine as the biopharmaceutical company attempts to bring it to North America, writes John George for the Philadelphia Business Journal.
Ocugen partnered with India-based Bharat Biotech last year, together producing a COVID-19 vaccine called Covaxin. It was administered to about 50 million children in India, and the positive results were published in The Lancet Infectious Diseases medical journal.
Shankar Musunuri, the CEO and co-founder of Ocugen, said the results were a “very encouraging development in the effort to contain this pandemic, which needs a greater variety of vaccine options to combat the multiple COVID-19 variants.”
Already approved in India and two dozen other countries, the two companies are working to receive approval for the U.S., Canada, and Mexico.
Currently, Ocugen is carrying out late-stage clinical trials for the vaccine in the U.S. It believes that Covaxin will be a “valuable tool” for immunization efforts.
Read more about Covaxin in the Philadelphia Business Journal.